Skip to main content

Table 4 Follow-up data: 6 months post-PRB initiation

From: Evaluating the feasibility of prolonged-release buprenorphine formulations as an alternative to daily opioid agonist therapy regardless of prior treatment adherence: a pilot study

 

Group 1 (n = 5*)

Group 2 (n = 7*)

UDS or self-reported, n (%)

 Buprenorphine

5 (100)

7 (100)

 Methadone

0 (0)

0 (0)

 Cocaine

0 (0)

2 (29)

 Morphine/heroin

0 (0)

3 (43)

 Benzodiazepine

0 (0)

0 (0)

 Amphetamine

0 (0)

0 (0)

Negative for on-top drug use, n (%)

5 (100)

4 (57)

  1. *UDS was not performed in one participant from group 1 and two participants from group 2 due to COVID-19 restrictions. Where a sample for UDS could not be collected, self-reported drug use was recorded instead. Follow-up data could not be collected for a further three participants from group 2, who withdrew from the study early
Back to article page

Pilot and Feasibility Studies

ISSN: 2055-5784